Physician profile
Paul Gilbert Johnson
NPI 1497790661
$534.91
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $55.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.92 | 2019 | |
| Pfizer INC. | $60.82 | 2019-2020 | |
| Allergan, INC. | $51.55 | 2019-2020 | |
| Grifols USA, LLC | $42.24 | 2019 | |
| Astellas Pharma US INC | $37.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.54 | 2019 | |
| Lilly USA, LLC | $26.78 | 2019 | |
| Merck Sharp & Dohme LLC | $26.72 | 2019 | |
| Abbott Laboratories | $21.09 | 2019 | |
| Amgen INC. | $20.59 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.84 | 2020 | |
| Endogastric Solutions, INC | $14.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.